Sana Biotechnology/SANA

$8.45

1.99%
-
1D1W1MYTD1YMAX

About Sana Biotechnology

Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, and genetic disorders, among others. The Company is applying its hypoimmune technology to donor derived T cells to be used as allogeneic cell therapies for hematologic malignancies. Its most advanced hypoimmune product candidate is SC291, a CD19-directed allogeneic CAR T program for the treatment of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL). It is also developing SC262, a CD22-directed allogeneic CAR T for the treatment of NHL, CLL, and ALL, as well as SC255, a B cell maturation antigen (BCMA)-directed allogeneic CAR T, for the treatment of multiple myeloma (MM).

Ticker

SANA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Steven Harr

Employees

424

Headquarters

Seattle, United States
Website
sana.com

SANA Metrics

BasicAdvanced
$1.78B
Market cap
-
P/E ratio
-$1.44
EPS
-
Beta
-
Dividend rate

What the Analysts think about SANA

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 6 analysts.
10.41% upside
High $13.00
Low $5.00
$8.45
Current price
$9.33
Average price target

SANA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$900K
-100.79%
Profit margin
0%
-

SANA Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 104.48%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.38
-$0.43
-$0.59
$0.02
-
Expected
-$0.52
-$0.45
-$0.43
-$0.45
-$0.38
Surprise
-26.21%
-3.73%
38.28%
-104.48%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Sana Biotechnology stock

Buy or sell Sana Biotechnology stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing